# Prevention of Complications (SARS-CoV-2): Clinical Study

> **NCT04788355** · PHASE3 · COMPLETED · sponsor: **Universidade do Vale do Sapucai** · enrollment: 176 (actual)

## Conditions studied

- Complication

## Interventions

- **DRUG:** Control group (standard hospital treatment)
- **DRUG:** Group Hydroxychloroquine
- **DRUG:** Group Hydroxychloroquine and apixaban
- **DRUG:** Group Apixaban

## Key facts

- **NCT ID:** NCT04788355
- **Lead sponsor:** Universidade do Vale do Sapucai
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-01
- **Primary completion:** 2020-11-15
- **Final completion:** 2020-12-23
- **Target enrollment:** 176 (ACTUAL)
- **Last updated:** 2021-03-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04788355

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04788355, "Prevention of Complications (SARS-CoV-2): Clinical Study". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04788355. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*